Atyr Pharma Inc [ATYR] stock is trading at $3.25, up 0.31%. An important factor to consider is whether the stock is rising or falling in short-term value. The ATYR shares have gain 8.70% over the last week, with a monthly amount glided 86.78%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Atyr Pharma Inc [NASDAQ: ATYR] stock has seen the most recent analyst activity on October 04, 2024, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $17. Previously, Jefferies started tracking the stock with Buy rating on September 05, 2024, and set its price target to $9. On July 05, 2023, downgrade downgraded it’s rating to Perform. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $22 on October 12, 2021. Piper Sandler initiated its recommendation with a Overweight and recommended $19 as its price target on September 21, 2021. Laidlaw started tracking with a Buy rating for this stock on May 10, 2021, and assigned it a price target of $18. In a note dated August 17, 2020, H.C. Wainwright upgraded an Buy rating on this stock but restated the target price of $13.
Atyr Pharma Inc [ATYR] stock has fluctuated between $1.08 and $3.54 over the past year. Atyr Pharma Inc [NASDAQ: ATYR] shares were valued at $3.25 at the most recent close of the market.
Analyzing the ATYR fundamentals
Gross Profit Margin for this corporation currently stands at -3.34% with Operating Profit Margin at -106.34%, Pretax Profit Margin comes in at -98.46%, and Net Profit Margin reading is -98.46%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -0.65 and Total Capital is -0.66. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.12 points at the first support level, and at 3.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.41, and for the 2nd resistance point, it is at 3.58.
Ratios To Look Out For
For context, Atyr Pharma Inc’s Current Ratio is 7.63. On the other hand, the Quick Ratio is 7.63, and the Cash Ratio is 0.57. Considering the valuation of this stock, the price to sales ratio is 417.54, the price to book ratio is 3.02.
Transactions by insiders
Recent insider trading involved SCHIMMEL PAUL, Director, that happened on Jul 24 ’24 when 52300.0 shares were purchased. Director, SCHIMMEL PAUL completed a deal on Jul 22 ’24 to buy 41052.0 shares. Meanwhile, Director SCHIMMEL PAUL bought 6648.0 shares on Jul 23 ’24.
